{"id":"a5ee0c1b15ba","type":"article","url":"https://hartvaat.nl/2022/07/21/permanente-pacemaker-na-tavi-langetermijneffect-op-klinische-uitkomsten/","title":"Permanente pacemaker na TAVI: langetermijneffect op klinische uitkomsten","title_en":"Long-term clinical impact of permanent pacemaker implantation in patients undergoing transcatheter aortic valve implantation: a systematic review and meta-analysis.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["aortastenose","tavi"],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euac008","source_url":"https://doi.org/10.1093/europace/euac008","authors":["Andrea Zito","Giuseppe Princi","Marco Lombardi","Domenico D'Amario","Rocco Vergallo","Cristina Aurigemma","Enrico Romagnoli","Gemma Pelargonio","Piergiorgio Bruno","Carlo Trani","Francesco Burzotta","Filippo Crea"],"significance":7,"published":"2022-07-21","source_date":"2022-07-21","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/digoxine-bij-hartfalen/","https://hartvaat.nl/kennis/diagnostiek/galectine-3-st2-hartfalen/"],"congress":"","summary_en":"This meta-analysis confirmed that permanent pacemaker implantation after TAVR is associated with higher long-term mortality and more heart failure hospitalizations, highlighting the importance of minimizing conduction complications during transcatheter valve procedures.","created":"2026-07-03T10:29:50Z","updated":"2026-07-03T13:28:56Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"Meta-analyse toonde dat permanente pacemakerimplantatie na TAVI geassocieerd is met hogere mortaliteit en meer hartfalenhospitalisaties op lange termijn. Dit benadrukt het belang van strategieën om geleidingsstoornissen na TAVI te minimaliseren.","abstract_original":"AIMS: The aims of this study is to assess by an updated meta-analysis the clinical outcomes related to permanent pacemaker implantation (PPI) after transcatheter aortic valve implantation (TAVI) at long-term (≥12 months) follow-up (LTF). METHODS AND RESULTS: A comprehensive literature research was performed on PubMed and EMBASE. The primary endpoint was all-cause death. Secondary endpoints were rehospitalization for heart failure, stroke, and myocardial infarction. A subgroup analysis was performed according to the Society of Thoracic Surgeon-Predicted Risk of Mortality (STS-PROM) score. This study is registered with PROSPERO (CRD42021243301). A total of 51 069 patients undergoing TAVI from 31 observational studies were included. The mean duration of follow-up was 22 months. At LTF, PPI post-TAVI was associated with a higher risk of all-cause death [risk ratio (RR) 1.18, 95% confidence interval (CI) 1.10-1.25; P < 0.001] and rehospitalization for heart failure (RR 1.32, 95% CI 1.13-1.52; P < 0.001). In contrast, the risks of stroke and myocardial infarction were not affected. Among the 20 studies that reported procedural risk, the association between PPI and all-cause death risk at LTF was statistically significant only in studies enrolling patients with high STS-PROM score (RR 1.25, 95% CI 1.12-1.40), although there was a similar tendency of the results in those at medium and low risk. CONCLUSION: Patients necessitating PPI after TAVI have a higher long-term risk of all-cause death and rehospitalization for heart failure as compared to those who do not receive PPI."}